Mitre Medical


Mitre Medical Corp. announces the initial clinical trial enrollment for beating heart surgical mitral regurgitation (MR) reduction with the Mitral Touch® device.

01/26/2018 –This less invasive procedure offers an alternative approach to mitigate moderate to severe mitral regurgitation.

Silicon Valley, 01/26/2018 – Mitre Medical Corp. announces the initial enrollment of patients treated with the Mitral Touch epicardial annuloplasty device. The procedures were performed by cardiac surgeons Kestutis Rucinskas, MD, Ph.D. and Gintaras Kalinauskas, M.D. of Vilnius University Hospital Santaros Klinikos, Cardiac Surgery Center in Vilnius, Lithuania.

The Mitral Touch is an epicardial, less-invasive surgical solution to treat functional mitral regurgitation, facilitate reverse ventricular remodeling and potentially prevent the onset of congestive heart failure.  Mitral Touch emulates the standard of care – mitral annuloplasty rings, with the empowering feature of not requiring surgeons to stop the heart and place patients on the Heart-Lung Bypass Machine.  The Mitral Touch sits on the outside of the heart, providing annular and sub-annular support for MR reduction. The potential benefits include shorter procedure time, less complications and shorter hospital stays.

“The Mitral Touch holds the promise of a less invasive and safer approach to treat patients with mitral valve regurgitation,” says John MacMahon, CEO of Mitre Medical Corp. “The Mitral Touch was designed to empower surgeons to assess MR reduction on a beating heart prior to implantation. In this initial patient series, we can confirm that acutely – indeed it does.”

“Mitral valve repair is the treatment of choice for patients with mitral valve regurgitation. Deployment of the Mitral Touch device is an easy and straightforward treatment that unlocks the benefits of valve repair for patients we have been unable to treat with currently available devices,” states Kestutis Rucinskas, M.D., Ph.D.

Gintaras Kalinauskas, M.D. adds: “Since the procedure is performed on the beating heart,  implantation time of the Mitral Touch device is fast. This paves the way for the treatment of a wider range of patients with mitral regurgitation who, due to their state of health, would be too fragile for a conventional surgery.”

The Mitral Touch device is currently not approved by the FDA and is not CE marked.

About Mitre Medical Corp.
Mitre Medical Corp. is a medical device company with headquarters in Silicon Valley. The focus of the company is the development of innovative solutions to treat structural heart disease.

Contact information:

Mitre Medical Corp.
John MacMahon, CEO